| Dr Thomas F Della Torre, MD | |
|
148 W River St, Suite 2a, Providence, RI 02904-2615 | |
| (401) 728-0140 | |
| (401) 727-1979 |
| Full Name | Dr Thomas F Della Torre |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 22 Years |
| Location | 148 W River St, Providence, Rhode Island |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720204480 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207YX0905X | Otolaryngology - Otolaryngology/facial Plastic Surgery | MD12716 (Rhode Island) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Our Lady Of Fatima Hospital | North providence, RI | Hospital |
| Rhode Island Hospital | Providence, RI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ri Ear Nose And Throat Physicians Inc | 8921109448 | 9 |
News Archive
The battlefield of the future may react differently to combat injuries, providing instant treatment to wounded soldiers even before a medic reaches their side.
A single protein plays a major role in deadly prion diseases by smashing up clusters of these infectious proteins, creating the "seeds" that allow fatal brain illnesses to quickly spread, new Brown University research shows.
A research team at KAIST reported clinically accurate multiplexed electrical biosensor for detecting Alzheimer's disease by measuring its core biomarkers using densely aligned carbon nanotubes.
e-Therapeutics plc today provides an update on the clinical trials of its cancer drug ETS2101. Two phase I studies, one in patients with primary or secondary brain cancer and the other in patients with various solid tumours, remain on track to report final data in Q4 2013 and Q1 2014, respectively. Interim data from the trials are expected in H1 2013.
› Verified 9 days ago
| Entity Name | Ri Ear Nose & Throat Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093861049 PECOS PAC ID: 8921109448 Enrollment ID: O20070726000805 |
News Archive
The battlefield of the future may react differently to combat injuries, providing instant treatment to wounded soldiers even before a medic reaches their side.
A single protein plays a major role in deadly prion diseases by smashing up clusters of these infectious proteins, creating the "seeds" that allow fatal brain illnesses to quickly spread, new Brown University research shows.
A research team at KAIST reported clinically accurate multiplexed electrical biosensor for detecting Alzheimer's disease by measuring its core biomarkers using densely aligned carbon nanotubes.
e-Therapeutics plc today provides an update on the clinical trials of its cancer drug ETS2101. Two phase I studies, one in patients with primary or secondary brain cancer and the other in patients with various solid tumours, remain on track to report final data in Q4 2013 and Q1 2014, respectively. Interim data from the trials are expected in H1 2013.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Thomas F Della Torre, MD 148 W River St Ste 2a, Providence, RI 02904-2615 Ph: (401) 728-0140 | Dr Thomas F Della Torre, MD 148 W River St, Suite 2a, Providence, RI 02904-2615 Ph: (401) 728-0140 |
News Archive
The battlefield of the future may react differently to combat injuries, providing instant treatment to wounded soldiers even before a medic reaches their side.
A single protein plays a major role in deadly prion diseases by smashing up clusters of these infectious proteins, creating the "seeds" that allow fatal brain illnesses to quickly spread, new Brown University research shows.
A research team at KAIST reported clinically accurate multiplexed electrical biosensor for detecting Alzheimer's disease by measuring its core biomarkers using densely aligned carbon nanotubes.
e-Therapeutics plc today provides an update on the clinical trials of its cancer drug ETS2101. Two phase I studies, one in patients with primary or secondary brain cancer and the other in patients with various solid tumours, remain on track to report final data in Q4 2013 and Q1 2014, respectively. Interim data from the trials are expected in H1 2013.
› Verified 9 days ago
Dr. Paul C Christu, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 845 N Main St, Suit 1, Providence, RI 02904 Phone: 401-331-9690 Fax: 401-331-9609 | |
Charles M Ruhl, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 118 Dudley St, Providence, RI 02905 Phone: 401-274-2300 Fax: 401-272-1302 | |
Pamela D Dana-snyder, M.D. Otolaryngology Medicare: Medicare Enrolled Practice Location: 830 Chalkstone Ave, Providence, RI 02908 Phone: 401-273-7000 Fax: 401-457-1460 | |
Peter T Nigri, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 118 Dudley St, Providence, RI 02905 Phone: 401-274-2300 Fax: 401-272-1302 | |
David Samuel Bick, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 148 W River St, Suite 2a, Providence, RI 02904 Phone: 401-728-0140 Fax: 401-727-1979 | |
Jan Casimir Groblewski, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 118 Dudley St, Providence, RI 02905 Phone: 401-274-2300 | |
Dr. Frederick Augustus Godley Iii, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 845 N Main St, Suite 1, Providence, RI 02904 Phone: 401-331-9690 Fax: 401-331-9609 |